Innovent Options China Rights to Amagma's Inflammatory Disease Inhibitors

Suzhou Innovent Bio optioned China rights to develop up to three enzyme specific inhibitors for inflammatory diseases from Amagma Therapeutics, a Massachusetts company. The candidates are products of Amagma’s structure-based SEIZMIC™ Platform. Innovent will be responsible for manufacturing the three candidates through a Phase II study conducted by Amagma. If Innovent exercises its option, it will have Greater  China rights to develop and commercializef each program, and Amagma will be eligible to receive milestones plus royalties. More details.... Stock Symbol: (HK: 01801) Share this with colleagues: // //